4//SEC Filing
Tenbarge Bryce 4
Accession 0001437749-20-013679
CIK 0000835887other
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 4:49 PM ET
Size
14.5 KB
Accession
0001437749-20-013679
Insider Transaction Report
Form 4
Tenbarge Bryce
Vice President, Commercial
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−75,000→ 0 totalExercise: $6.77Exp: 2026-10-02→ Common Stock (75,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−66,000→ 0 totalExercise: $11.32Exp: 2027-02-28→ Common Stock (66,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−75,900→ 0 totalExercise: $6.62Exp: 2028-02-29→ Common Stock (75,900 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−90,750→ 0 totalExercise: $4.52Exp: 2029-03-01→ Common Stock (90,750 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−82,214→ 0 totalExercise: $4.77Exp: 2030-03-02→ Common Stock (82,214 underlying)
Footnotes (6)
- [F1]This option is scheduled to vest in annual installments over the five-year period commencing September 1, 2016.
- [F2]On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the current vesting and other terms of the option continue in effect.
- [F3]This option is fully vested and exercisable.
- [F4]This option is scheduled to vest in annual installments over the three-year period commencing March 1, 2018.
- [F5]This option is scheduled to vest in annual installments over the three-year period commencing March 1, 2019.
- [F6]This option is scheduled to vest in annual installments over the three-year period commencing March 2, 2020.
Documents
Issuer
PROGENICS PHARMACEUTICALS INC
CIK 0000835887
Entity typeother
Related Parties
1- filerCIK 0001682907
Filing Metadata
- Form type
- 4
- Filed
- Jun 22, 8:00 PM ET
- Accepted
- Jun 23, 4:49 PM ET
- Size
- 14.5 KB